Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis
- PMID: 15155183
- PMCID: PMC415620
- DOI: 10.1128/AAC.48.6.1948-1952.2004
Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis
Abstract
The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of Staphylococcus aureus isolates of diverse antibiotic susceptibilities. Rabbit eyes were intrastromally injected with approximately 100 CFU of methicillin-sensitive or methicillin-resistant S. aureus (MSSA or MRSA, respectively) organisms that were either sensitive or resistant to ofloxacin. One drop of moxifloxacin (0.5%), levofloxacin (0.5%), or ciprofloxacin (0.3%) was topically applied hourly from 4 to 9 (early) or 10 to 15 (late) h postinfection. At 1 h after cessation of therapy, the corneas were harvested, and the number of CFU per cornea was determined. For the ofloxacin-sensitive strains, early treatment of MSSA or MRSA with moxifloxacin, levofloxacin, or ciprofloxacin produced approximately a 5-log decrease in CFU per cornea relative to that in untreated eyes (P </= 0.0001). For late therapy of ofloxacin-sensitive strains, moxifloxacin, levofloxacin, and ciprofloxacin produced approximately 5-, 4-, and 2- to 3-log reductions in CFU per cornea, respectively (P </= 0.0001). Early treatment of the ofloxacin-resistant strains with either moxifloxacin or levofloxacin produced a >/=4-log or >/=3-log decrease, respectively, in the MSSA or MRSA strains (P </= 0.0001), whereas ciprofloxacin treatment produced a 1-log decrease in CFU per cornea relative to that in untreated eyes (P = 0.1540). For late treatment of ofloxacin-resistant strains, levofloxacin and ciprofloxacin failed to significantly reduce the number of CFU per cornea (P >/= 0.3627), whereas moxifloxacin produced a significant reduction in CFU per cornea of approximately 1 log (P </= 0.0194). Therefore, for three of the four treatments tested, moxifloxacin demonstrated greater effectiveness than either levofloxacin or ciprofloxacin.
Figures


Similar articles
-
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.Curr Eye Res. 2006 Jan;31(1):23-9. doi: 10.1080/02713680500477321. Curr Eye Res. 2006. PMID: 16421016
-
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.Curr Eye Res. 2004 May;28(5):337-42. doi: 10.1076/ceyr.28.5.337.28676. Curr Eye Res. 2004. PMID: 15287370
-
Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model.Curr Eye Res. 1998 Aug;17(8):808-12. Curr Eye Res. 1998. PMID: 9723996
-
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.Adv Ther. 2008 Oct;25(10):979-94. doi: 10.1007/s12325-008-0107-x. Adv Ther. 2008. PMID: 18836691 Review.
-
Efficacy of fluoroquinolones against pathogenic oral bacteria.Mini Rev Med Chem. 2009 Sep;9(10):1147-58. doi: 10.2174/138955709789055243. Mini Rev Med Chem. 2009. PMID: 19534690 Review.
Cited by
-
Effect of formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas.AAPS PharmSciTech. 2006 Feb 10;7(1):E13. doi: 10.1208/pt070113. AAPS PharmSciTech. 2006. PMID: 16584143 Free PMC article.
-
Animal models of bacterial keratitis.J Biomed Biotechnol. 2011;2011:680642. doi: 10.1155/2011/680642. Epub 2011 Jan 4. J Biomed Biotechnol. 2011. PMID: 21274270 Free PMC article. Review.
-
Investigation of moxifloxacin loaded chitosan-dextran nanoparticles for topical instillation into eye: In-vitro and ex-vivo evaluation.Int J Pharm Investig. 2014 Oct;4(4):164-73. doi: 10.4103/2230-973X.143114. Int J Pharm Investig. 2014. PMID: 25426437 Free PMC article.
-
Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review.BMC Infect Dis. 2014 Mar 13;14:140. doi: 10.1186/1471-2334-14-140. BMC Infect Dis. 2014. PMID: 24624933 Free PMC article.
-
Evaluation of the levofloxacin release characters from a rabbit foldable capsular vitreous body.Int J Nanomedicine. 2012;7:1-10. doi: 10.2147/IJN.S25268. Epub 2011 Dec 30. Int J Nanomedicine. 2012. PMID: 22275817 Free PMC article.
References
-
- Adams, D. E., E. M. Shekhtman, E. L. Zechiedrich, M. B. Schmidt, and N. R. Cozzarelli. 1992. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell 71:277-288. - PubMed
-
- Alexandrakis, G., E. C. Alfonso, and D. Miller. 2000. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 107:1497-1502. - PubMed
-
- Biedenbach, D. J., and R. N. Jones. 1996. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn. Microbiol. Infect. Dis. 25:47-51. - PubMed
-
- Callegan, M. C., J. A. Hobden, J. M. Hill, M. S. Insler, and R. J. O'Callaghan. 1992. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Investig. Ophthalmol. Vis. Sci. 33:3017-3023. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical